As molecularly informed treatment strategies are becoming increasingly feasible as first-line options, identifying a tumor’s mutational makeup, including directly targetable alterations, will be essential in guiding patients toward optimal treatment, as demonstrated by targeting BRAF V600E, FGFR, ALK and NTRK in (among others) pediatric gliomas27–32. Here, ALK is linked to neoplasm.